Anthropic wants to develop its own drugs (www.theverge.com)

Anthropic has unveiled Claude Science, an integrated AI workbench designed to streamline the scientific research process by consolidating various tools and datasets. At the “AI for Science” event, the company emphasized that this technology could significantly accelerate drug discovery and healthcare interventions, highlighting its existing partnerships with biotech and pharma companies. In a bold move, Anthropic also announced its intent to venture into drug development, with a focus on creating treatments for neglected diseases, signaling a pivotal shift from software provider to active participant in drug discovery. This initiative places Anthropic within an emerging competitive landscape of AI-driven drug development, joining established players like Insilico and Google DeepMind spinout Isomorphic Labs. However, the path to successful drug commercialization remains long and uncertain, as experts point out that while AI can enhance various stages of drug discovery—from identifying new compounds to data analysis—real-world testing and the need for human oversight make the process slow and complex. Anthropic's recruitment of biologists and investment in lab facilities indicates a commitment to this endeavor, but the effectiveness of AI in ultimately delivering viable drugs to market is still a long way off, with potential payoffs likely a decade away.